CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 85 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03203473
NCT03203473Phase 2Active
CompareCT.gov

Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)

Toni Choueiri, MD·interventional·Posted Jun 29, 2017·Updated Feb 6, 2026

In Brief

A Phase 2 clinical trial evaluating Ipilimumab and Nivolumab for Renal Cancer. Active but no longer recruiting, targeting 85 participants across 8 sites.

Detailed Summary

This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2ActiveOverdue
201820192020202120222023202420252026
First PostedJun 29, 2017
Enrollment StartOct 26, 2017
Primary CompletionNov 30, 2021
Study CompletionJun 28, 2026
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.0 years ago

Interventions

Ipilimumabdrug

YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells

Nivolumabdrug

Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs